Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04601532 · ClinicalTrials.gov registry record · Phase 4
Superficial Partial-Thickness Burn Study
A Phase 4 study, sponsored by J. Peter Rubin, MD.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04601532 is a Phase 4 study that was terminated before completion, run by J. Peter Rubin, MD. The registered enrollment target is 26 participants.
The verdict
NCT04601532, a Phase 4 study, was terminated before completion, sponsored by J. Peter Rubin, MD.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). Both groups will receive the same care other than the treating agent. Subjects will be recruited form the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness burn wounds that comprise less than or equal to 10% of total body surface area (TBSA)
Interventions
- DEVICE Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser
- DRUG Silver Sulfadiazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04601532
The ClinicalTrials.gov registry entry for NCT04601532 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is J. Peter Rubin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser is the first listed.
NCT04601532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04601532 about?
NCT04601532 is a clinical study titled "Superficial Partial-Thickness Burn Study". This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). B...
What is the current status of trial NCT04601532?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2021-06-11. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT04601532?
The interventions under investigation include: Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser (DEVICE), Silver Sulfadiazine (DRUG).
Who is sponsoring clinical trial NCT04601532?
This trial is sponsored by J. Peter Rubin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.